A Phase A Phase 2 Randomized Double-Blind Double-Dummy Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide and the Fixed-Dose Combination of Cilofexor and Firsocostat Alone and in Combination in Subjects with Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)

Go Back to All Clinical Trials

A Phase A Phase 2 Randomized Double-Blind Double-Dummy Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide and the Fixed-Dose Combination of Cilofexor and Firsocostat Alone and in Combination in Subjects with Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)

Brief description of study

The purpose of this study is to see if the investigational drugs semaglutide, the fixed-dose combination of CILO/FIR, and their combination are safe and well tolerated in people with liver cirrhosis from NASH and whether these drugs can help reduce inflammation and fibrosis in the liver.

Clinical Study Identifier: s22-01109

ClinicalTrials.gov Identifier: NCT04971785

Principal Investigator: Ira M. Jacobson.

Other Investigator: Mary Christine Olson.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies

Brief description of study

Recruitment Status

Contact the research team to learn more about this study.

Recruitment Status

212-263-4432

646-754-7432